Fenofibrate, GLP-1 Agonists and Diabetic Retinopathy: What Residents Should Know

Last updated: October 2026

Diabetic retinopathy is treated in the eye, but its course is set by the rest of the body. Two drug stories matter right now: fenofibrate, which the 2024 LENS trial showed slows progression, and GLP-1 receptor agonists such as semaglutide, which can cause early worsening in some patients. Both come up in clinic every week.

The basics first

• Glucose: DCCT (type 1) and UKPDS (type 2) established that tight control reduces the onset and progression of retinopathy.
• Blood pressure: UKPDS showed tight blood pressure control reduced retinopathy progression and the need for laser.
• Early worsening: a rapid, large fall in HbA1c can transiently worsen retinopathy, particularly when it is already moderate or worse. The long-term benefit of control still wins, but these eyes need closer follow-up.

Fenofibrate: three trials to know

• Mechanism: fenofibrate is a PPAR-α agonist. Its retinal benefit seems largely independent of lipid lowering, through anti-inflammatory, anti-apoptotic and vascular effects.
• Safety: it causes a reversible rise in serum creatinine, needs dose adjustment in renal impairment, and carries a myopathy risk that is higher with statins. It is not a drug for ophthalmologists to start alone.
• In practice: for patients with mild to moderate NPDR or early maculopathy, it is reasonable to write to the physician suggesting fenofibrate be considered. Australia's regulator (TGA) approved it "to slow the progression of existing diabetic retinopathy in patients with type 2 diabetes".

GLP-1 receptor agonists and retinopathy

• The signal: in SUSTAIN-6 (NEJM 2016, 3,297 patients), semaglutide was associated with more retinopathy complications than placebo: 3.0% vs 1.8% (HR 1.76). Most events occurred in patients with pre-existing retinopathy and a large, rapid fall in HbA1c, which fits the early-worsening pattern.
• Real-world data: an AAO IRIS Registry analysis of more than 48,000 semaglutide users found that only a small proportion of eyes worsened over two years. It had no control group, so it cannot settle the question.
• The definitive answer is pending: the FOCUS trial is following eyes on semaglutide with standardised ETDRS grading and is expected to finish around 2027.
• Separate issue: semaglutide has also been linked to NAION. See our post on semaglutide and NAION.

A practical approach in clinic

Viva pearls

• Fenofibrate works in the eye largely independently of lipid lowering. Explain this as a PPAR-α effect.
• LENS was embedded in a national screening programme, which made it pragmatic and large at low cost.
• Early worsening is classically described with the start of intensive insulin in DCCT, and also in pregnancy and after bariatric surgery.
• SGLT2 inhibitors have been associated with less retinopathy progression in observational studies, but this is not proven in randomised trials.

Related: diabetic retinopathy classification and management, ICO guidelines for diabetic eye care and OCT biomarkers in DMO.

Key sources

• University of Oxford: LENS trial results (2024)
• American Diabetes Association: LENS press release
• AAO: IRIS Registry semaglutide analysis (2023)
• NHS HRA: FOCUS trial summary
• Keech AC et al. FIELD study. Lancet 2007;370:1687–97
• ACCORD Study Group and ACCORD Eye Study Group. NEJM 2010;363:233–44
• Marso SP et al. SUSTAIN-6. NEJM 2016;375:1834–44